| Position | Action |
|---|---|
| Current levels ($404) | Trim 30–40% of UNH exposure |
| Residual position | Deploy $400/$365 put spread hedge (60–90 DTE, 25–33% of residual position) |
| Close above 10 EMA at $414.86 with MACD turning less negative | Add back the trim |
| Flush to $385–$395 with capitulation volume | Add aggressively |
UNH's technical weakness is a buying opportunity within a structural bull market, as the 200 SMA ($342.65) remains intact, forward valuation (18.01x P/E) is fair, Q1 2026 confirmed earnings recovery (EPS $6.90, 8.0% margin), and the margin gap that concerns bears will drive re-rating to 22-25x when Q3 earnings validate recovery.
| Indicator | Value | Signal |
|---|---|---|
| 10 EMA | $414.86 | bearish |
| 50 SMA | $411.75 | bearish |
| 200 SMA | $342.65 | bullish |
| RSI (14) | 41.84 | bearish |
| MACD | -0.88 | bearish |
| MACD Signal | +2.29 | neutral |
| MACD Histogram | -3.17 | bearish |
| Bollinger Upper Band | $436.83 | bearish |
| Bollinger Lower Band | $405.46 | bullish |
| ATR (14) | $12.24 | bearish |
| Close (08-06) | $403.97 |
This report is AI-generated for informational and educational purposes only and is not investment advice or a recommendation to buy or sell any security. Full disclaimer.
Underweight: Trim 30–40% ahead of binary Q3 2026 catalyst with mandatory put spread hedge
Underweight rating is mechanically a trim-and-retain operation (not full exit) justified by: technical lower-high/lower-low sequence ($436.35→$428.79→$414.40→$407.55→$403.97) below both 10 EMA and 50 SMA for the first time since rally began; buyback pause since H2 2025 signals management doesn't view equity as undervalued at $414; pure Hold has destroyed alpha twice in 2026 (August 3 at -3.7%, August 5 at -2.0%); and Q3 print overlaps with compressed four-week catalyst window (AEP Oct 15, 2027 MA bid commentary). Underweight is not full Sell due to Optum moat, Forward P/E of 18, Q1 2026 recovery, and beta of 0.63—Underweight with mandatory hedge overlay structurally fixes the alpha-destruction pattern.
When: Flush to $385–$395 with capitulation volume
Then: Add aggressively
Forward P/E of 18.01 is reasonable, not expensive, as TTM metrics are distorted by one-time Q4 2025 items.
↩ rebuts: “Operating margin gap is the central risk”
· concedes: The tape looks weak — bear concerns about MACD crossing below zero and RSI trending toward oversold are technically valid; CVS 2027 commentary did spook the sector; Stock is already up significantly from lows (70% off low); Buybacks are paused — though de-leveraging and cash building signal imminent resumption; MA 2027 plan changes are a legitimate wildcard, though UNH has been more disciplined than peers in MA repricing
UNH at $403.97 is not buying the dip — it's buying into a regime change where deteriorating technicals, premium valuation on unproven earnings recovery, hidden balance sheet fragility, and macro headwinds combine to create an unattractive risk-adjusted return.
· concedes: Moat is real and vertically integrated (UNH + OptumHealth + OptumInsight + OptumRx); Q1 2026 did show margin recovery (5.6% net margin vs 3.1% in Q2 2025); Q2 institutional data shows some funds were buyers through June 30; FCF generation is historically strong ($22.76B annually); Disciplined MA repricing is a real competitive advantage, just with limits
→ vs conservative: The 200 SMA at $342 is not a comfort zone but a freefall runway with 15% downside vacuum; being 'below' the 200 SMA cushion means it represents the next support IF support breaks, not protection
→ vs conservative: Forward P/E of 18x on $22.44 EPS is not a floor—it becomes a ceiling if margins disappoint and multiple compresses from 18x to 14x-12x, targeting $280 not $385
→ vs conservative: 30-40% trim is half-committed; if bear case to $340-$380 plays out, leaving 60-70% exposed to capture only $25-$65 drawdown contradicts the thesis
→ vs conservative: The 'diversified engine' with Optum is real moat but preserves only a smaller core position—not an argument for full exposure through binary catalyst
→ vs neutral: 'Wait for confirmation' is lagging indicator; by time Q3 prints mid-October and confirms margin failure, price already at $360 implying 12% loss had already occurred
→ vs neutral: Confirmation bias in this setup costs the highest price for clarity—positioning before event is the point of catalyst windows, not after
→ vs neutral: Three pre-event tells align (broken technicals, paused buybacks at $400-$415, Q3 binary + AEP overlap)—this is stacked evidence, not noise requiring post-event confirmation
| — |
Support: 405.46 · 400 | Resistance: 414.86 · 421.14 · 436.83
UNH exhibits a classic multi-timeframe divergence: short-term bearish alignment (price below 10 EMA and 50 SMA) contrasts with long-term bullish structure (price well above 200 SMA). The MACD crossed below zero on 2026-08-06 with histogram at -3.17, confirming accelerating downside momentum. Price is testing the lower Bollinger Band at $405.46 and the psychological $400 level—key support to monitor. ATR has risen to $12.24 (+36% from May), indicating elevated volatility that warrants wider stop-loss placement. The overall technical posture reflects a correction phase within a structural uptrend, with the next directional move likely determined by whether price bounces from current support or breaks decisively below $400.
Market Cap
$366.86 B
Revenue (TTM)
$450.13 B
Net Income (TTM)
$14.12 B
EPS (TTM)
$13.29
Forward EPS
$22.44
P/E (TTM)
30.40
Forward P/E
18.01
PEG Ratio
1.28
Price to Book
3.50
Operating Margin
7.13%
Net Margin
3.14%
Gross Profit (TTM)
$87.84 B
EBITDA (TTM)
$24.26 B
Return on Equity
14.15%
Return on Assets
4.38%
Free Cash Flow (TTM)
$22.76 B
FCF Yield
~6.2%
Dividends/Year
~$8 B
52-Week High
$461.62
52-Week Low
$239.50
50-Day Moving Average
$410.81
200-Day Moving Average
$344.97
Beta
0.632
Q1 2025 Revenue
$109.58 B
Q1 2025 Net Income
$6.29 B
Q1 2025 Diluted EPS
$6.85
Q1 2025 Operating Margin
8.3%
Q2 2025 Revenue
$111.62 B
Q2 2025 Net Income
$3.41 B
Q2 2025 Diluted EPS
$3.74
Q2 2025 Operating Margin
4.6%
Q3 2025 Revenue
$113.16 B
Q3 2025 Net Income
$2.35 B
Q3 2025 Diluted EPS
$2.59
Q3 2025 Operating Margin
3.8%
Q4 2025 Revenue
$113.22 B
Q4 2025 Net Income
$0.01 B
Q4 2025 Diluted EPS
$0.01
Q4 2025 Operating Margin
0.3%
Q1 2026 Revenue
$111.72 B
Q1 2026 Net Income
$6.28 B
Q1 2026 Diluted EPS
$6.90
Q1 2026 Operating Margin
8.0%
Q1 2026 Total Assets
$312.64 B
Q1 2026 Total Liabilities
$207.33 B
Q1 2026 Stockholders' Equity
$97.88 B
Q1 2026 Total Debt
$77.92 B
Q1 2026 Net Debt
$49.92 B
Q1 2026 Cash and Equivalents
$28.00 B
Goodwill
$110.51 B
Debt/Equity
69.21
Current Ratio
0.777
Q1 2026 Operating Cash Flow
$8.91 B
Q1 2026 CapEx
-$0.76 B
Q1 2026 Free Cash Flow
$8.15 B
Dividends Paid (Q1 2026)
$2.01 B
Recommendation
HOLD
Strengths
Concerns
UnitedHealth Group (UNH) is the largest diversified managed healthcare company in the U.S., operating through UnitedHealthcare (health benefits/insurance) and Optum (health services including pharmacy benefits, care delivery, and data analytics). With a market cap of ~$367 billion, UNH is a mega-cap S&P 500 bellwether. The company reported strong Q1 2026 recovery (EPS $6.90, Net Income $6.28B) after a catastrophic Q4 2025 (EPS $0.01) caused by Change Healthcare cyberattack remediation and elevated medical costs. TTM revenue stands at $450.13B with $14.12B net income, while free cash flow of $22.76B supports the dividend and balance sheet. Analysts project 69% earnings recovery to Forward EPS of $22.44, supporting a Forward P/E of 18.01. The HOLD recommendation reflects substantial recovery from 52-week lows already executed, with better risk-adjusted entry available on pullbacks toward the 200-day moving average (~$345).